Oncogenic KRAS drives radioresistance through upregulation of NRF2-53BP1-mediated non-homologous end-joining repair
Linlin Yang(City Of Hope National Medical Center), Terence M. Williams(City Of Hope National Medical Center)
Cited by 68
Related Papers
Targeting oncogenic KRAS in non-small cell lung cancer with EGFR aptamer-conjugated multifunctional RNA nanoparticles
|Molecular Therapy — Nucleic Acids|2023|24
TRPS1 regulates the opposite effect of progesterone via RANKL in endometrial carcinoma and breast carcinoma
|Cell Death Discovery|2023|7
Improved Targeting and Safety of Doxorubicin through a Novel Albumin Binding Prodrug Approach
|ACS Omega|2023|7
PGM3 insufficiency: a glycosylation disorder causing a notable T cell defect
|Frontiers in Immunology|2024|7
JNTX-101, a novel albumin-encapsulated gemcitabine prodrug, is efficacious and operates via caveolin-1-mediated endocytosis
|Molecular Therapy — Oncolytics|2023|6